Daymark Wealth Partners LLC Has $6.18 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Daymark Wealth Partners LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,733 shares of the biopharmaceutical company’s stock after selling 25,397 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Pfizer were worth $6,176,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter valued at approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.36 on Monday. The firm has a market capitalization of $132.81 billion, a PE ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business’s 50 day moving average is $22.95 and its 200-day moving average is $25.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 earnings per share. The business’s revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.